KPTI - Karyopharm rises as selinexor shows benefit in myelofibrosis in phase 2 interim data

Karyopharm Therapeutics (KPTI +0.4%) is rising on new data from a phase 2 study selinexor in patients with myelofibrosis (MF) who were resistant or intolerant to JAK inhibitors. MF is a type of bone marrow cancer that disrupts the body's ability to produce normal blood cells. The main goal of the study is to assess the efficacy of selinexor on spleen volume reduction (SVR). Median duration of prior JAK inhibitor therapy was 22 months and 11 out of 12 patients had MF refractory to ruxolitinib. In the nine patients who were on treatment for over 24 weeks, SVR of ?25% and 35% occurred in four and three patients, respectively. The most common treatment related adverse event was weight loss. This was manageable with treatment interruption and dose reduction, except in one patient who discontinued treatment. The company said overall, selinexor showed single-agent activity with sustained spleen responses in patients with JAK

For further details see:

Karyopharm rises as selinexor shows benefit in myelofibrosis in phase 2 interim data